EUVIMEDObjevte EUVIMED
Crossref

An Integrated Strategy to Identify Tyrosine Sulfation from the Therapeutic Proteins

Eunju Jang, Fengfei Ma iD, Daniela Tomazela, Laurence Fayadat-Dilman, Mohammad Ahmed Al-Sayah

Journal of the American Society for Mass Spectrometry · 2024

DOI: 10.1021/jasms.4c00303 ↗

At a glance

Journal article in Journal of the American Society for Mass Spectrometry, 2024. Written by Eunju Jang and 4 co-authors. Institution: Protein Sciences, Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States. Major MEDLINE topics: Tyrosine, Protein Processing, Post-Translational. Cited 1 times so far (Crossref); 34 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Posttranslational modifications (PTMs) are potential critical quality attributes in biotherapeutic development, as they can affect drug efficacy and safety. Tyrosine sulfation plays a critical role in protein-protein interactions and has been found on many surface receptors as well as antibody complementarity-determining regions (CDR). However, the presence and function of tyrosine sulfation in therapeutic proteins have not been broadly investigated due to difficulties in detecting the modification. Here, we establish an integrated strategy to identify tyrosine sulfation in biotherapeutic proteins. In silico prediction was used to estimate possible modification sites, followed by the elucidation with intact LCMS and native SCX-MS. The combination of these three steps takes less than 1 h, which provides quick and confident preliminary detection of potential CQAs. Taking NB1 as an example, three +80 Da mass shifts were observed from intact mass analysis and three acidic peaks were monitored by SCX, allowing confirmation of modification as either phosphorylation or sulfation. Peptide mapping, Fe3+-IMAC enrichment, and dephosphorylation were further conducted to provide improved signal intensity and differentiation of modification such as sulfation or phosphorylation. With this integrated strategy, we were able to identify for the first time both tyrosine sulfation and serine phosphorylation in one therapeutic protein.

Subjects

MeSH terms (MEDLINE)

TyrosineProtein Processing, Post-TranslationalPhosphorylationPeptide MappingProteinsSulfatesTandem Mass SpectrometryMass SpectrometryHumansAmino Acid Sequence

Author keywords

enrichmentmass spectrometrypeptide mappingphosphorylationsulfation

Substances

Tyrosinetyrosine O-sulfateProteinsSulfates

Authors and institutions

  • Protein Sciences, Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States.
  • Discovery Analytical Research, Analytical Enabling Capabilities, Merck & Co., Inc., South San Francisco, California 94080, United States.

ORCID profiles: Fengfei Ma

Cite

APA

Jang, E., Ma, F., Tomazela, D., Fayadat-Dilman, L., & Al-Sayah, M. A. (2024). An Integrated Strategy to Identify Tyrosine Sulfation from the Therapeutic Proteins. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.4c00303

Vancouver

Jang E, Ma F, Tomazela D, Fayadat-Dilman L, Al-Sayah MA. An Integrated Strategy to Identify Tyrosine Sulfation from the Therapeutic Proteins. Journal of the American Society for Mass Spectrometry. 2024. doi:10.1021/jasms.4c00303

BibTeX
@article{Jang2024,
  author = {Jang, Eunju and Ma, Fengfei and Tomazela, Daniela and Fayadat-Dilman, Laurence and Al-Sayah, Mohammad Ahmed},
  title = {An Integrated Strategy to Identify Tyrosine Sulfation from the Therapeutic Proteins},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {2024},
  doi = {10.1021/jasms.4c00303}
}
Start for free →